Trial
NCT05975905
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Keros Therapeutics, Inc.
Collaborators
—
Condition
Pulmonary Arterial Hypertension
Intervention
Dose A KER-012
Why stopped
The study was voluntarily terminated early, following a safety review and observation of pericardial effusions.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-02